ResearcherUniversity of OuluActive in the last 2 years
Heikki I. Huhta
Matched on ORCID iD 0000-0002-6273-198X; OpenAlex author ID A5088330644. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper
Papers 5
- Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. Co-author DOI 10.1186/s12893-025-02983-w↗
- Hospital volume and outcomes of pancreatic cancer: a Finnish population-based nationwide study. Co-author DOI 10.1016/j.hpb.2021.10.011↗
- Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001195↗
- Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-018-1432-4↗
- High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients. Co-author DOI 10.1007/s00428-017-2087-1↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Joonas H. Kauppila · 4 shared papers, 2017–2022 · strength 0.44
- Paper Hospital volume and outcomes of pancreatic cancer: a Finnish population-based nationwide study. DOI 10.1016/j.hpb.2021.10.011↗
- Paper Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001195↗
- Paper Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. DOI 10.1186/s12957-018-1432-4↗
- Joel Isohookana · 3 shared papers, 2017–2019 · strength 0.24
- Paper Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001195↗
- Paper Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. DOI 10.1186/s12957-018-1432-4↗
- Paper High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer … DOI 10.1007/s00428-017-2087-1↗
- Joni Leppänen · 3 shared papers, 2017–2019 · strength 0.24
- Paper Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001195↗
- Paper Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. DOI 10.1186/s12957-018-1432-4↗
- Paper High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer … DOI 10.1007/s00428-017-2087-1↗
- Tuomo J. Karttunen · 3 shared papers, 2017–2019 · strength 0.24
- Paper Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001195↗
- Paper Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. DOI 10.1186/s12957-018-1432-4↗
- Paper High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer … DOI 10.1007/s00428-017-2087-1↗
- Kirsi‐Maria Haapasaari · 3 shared papers, 2017–2019 · strength 0.24
- Paper Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001195↗
- Paper Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. DOI 10.1186/s12957-018-1432-4↗
- Paper High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer … DOI 10.1007/s00428-017-2087-1↗
- Christopher Månsson · 1 shared paper, 2025 · strength 0.20
- Nils O. Elander · 1 shared paper, 2025 · strength 0.20
- Bergþór Björnsson · 1 shared paper, 2025 · strength 0.20
- Asif Halimi · 1 shared paper, 2025 · strength 0.20
- Kristina Hasselgren · 1 shared paper, 2025 · strength 0.20
- Ernesto Sparrelid · 1 shared paper, 2025 · strength 0.20
- Poya Ghorbani · 1 shared paper, 2025 · strength 0.20
- Maria Gustafsson Liljefors · 1 shared paper, 2025 · strength 0.20
- Margareta Heby · 1 shared paper, 2025 · strength 0.20
- Daniel Öhlund · 1 shared paper, 2025 · strength 0.20
- Peeter Karihtala · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.